Verified peer comparison

AMGN vs VRTX

Amgen Inc. compared with Vertex Pharmaceuticals Incorporated. This page compares both source-verified company profiles and does not introduce an unverified price target.

AMGN

Amgen Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

VRTX

Vertex Pharmaceuticals Incorporated

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

AMGN: Biotechnology

VRTX: Biotechnology

Upside lens

AMGN: Broad volume growth across Repatha, EVENITY, rare-disease and oncology products can offset declines in mature brands. MariTide and other Phase 3 programs can create new growth franchises if clinical and regulatory milestones succeed. Expansion of UPLIZNA, IMDELLTRA and other newer medicines can diversify product growth.

VRTX: ALYFTREK and expanded eligible populations can sustain the core franchise and reach additional patients. CASGEVY and JOURNAVX adoption can establish meaningful franchises beyond cystic fibrosis. Povetacicept regulatory and late-stage progress can create a fourth major disease-area franchise.

Risk lens

AMGN: Competition is accelerating declines in Prolia, XGEVA and other established products. Medicare price setting, 340B mix, payer pressure and global reforms can reduce net selling prices. Clinical failures can impair growth expectations while acquisition-related debt and commitments limit flexibility.

VRTX: Cystic fibrosis remains the main revenue source and is exposed to pricing, access and future competition. Gene-editing and pain products face complex patient identification, delivery and reimbursement pathways. Late-stage failures or regulatory delays could materially reduce pipeline diversification value.